Submissions

Equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer
August 2023

Submissions

177Lutetium (n.c.a) Octreotate treatment for advanced neuroendocrine and other high somatostatin receptor expressing tumours (MSAC application 1744)
July 2023

Submissions

The Health Technology Assessment (HTA) Policy and Methods Review
June 2023

Submissions

Improvements to the Therapeutic Goods Recall Process Discussion Paper
March 2023

Submissions

Submission to the draft Australian Cancer Plan
December 2022

Submissions

Exercise & Cancer Group submission to the draft Australian Cancer Plan consultation
December 2022